Herbal Monograph
Artichoke Leaf
Cynara cardunculus var. scolymus (L.) Benth.
Asteraceae (Compositae)
Premier hepatobiliary bitter for digestive support, bile flow, and cholesterol management
Overview
Plant Description
Globe artichoke is a robust, architecturally striking, thistle-like herbaceous perennial growing 1.0-2.0 m (3-7 feet) tall with a stout, erect, grooved stem that becomes woody at the base. The basal rosette of leaves is the medicinal part: large (up to 50-80 cm / 20-32 inches long and 30-40 cm / 12-16 inches wide), deeply pinnatifid to pinnatipartite, with broad, toothed or lobed segments. The upper leaf surface is grey-green, while the lower surface is densely covered with fine white-grey tomentose (woolly) hairs giving a silvery appearance. The leaves have a characteristically bitter taste due to their sesquiterpene lactone content. IMPORTANT: The medicinal part is the LEAF (Cynarae folium), not the edible immature flower head (capitulum) commonly consumed as a vegetable. The flower heads are large, globose capitula (8-15 cm / 3-6 inches in diameter), composed of numerous fleshy, overlapping involucral bracts (phyllaries) surrounding a mass of tubular purple florets on a fleshy, edible receptacle. The florets are hermaphroditic, tubular, and deep violet-blue to purple when open. The fruit is an achene (cypsela) with a feathery pappus. The root system is a deep, fleshy taproot with lateral rootlets. The entire plant exudes a distinctive, slightly resinous, bitter-aromatic scent when bruised.
Habitat
Globe artichoke is cultivated extensively in the Mediterranean region, where it thrives in warm, temperate climates with mild winters and dry summers. It prefers deep, fertile, well-drained, slightly alkaline soils with good moisture retention. In its wild form (as Cynara cardunculus var. cardunculus), it grows in dry grasslands, hillsides, roadsides, and disturbed ground throughout the Mediterranean basin, from sea level to approximately 800 m elevation. It is not frost-hardy and is damaged by sustained temperatures below -5 degrees C, though the rootstock may survive brief frosts with mulch protection.
Distribution
The globe artichoke originated in the central and western Mediterranean region, with the wild cardoon ancestor distributed across southern Europe and North Africa. Italy is the world's largest producer, followed by Egypt, Spain, Peru, and Argentina. France, Turkey, Algeria, Morocco, and the United States (primarily California) are also significant producers. For medicinal leaf production, cultivation is concentrated in southern Europe (Italy, Spain, France, Germany) and parts of South America. The plant has been introduced and cultivated worldwide in Mediterranean-type climates, including California, Chile, Australia, and South Africa.
Parts Used
Leaf (Cynarae folium)
Preferred: Dried leaf for extract preparation; standardized dry extract (DER 4-7:1, extraction solvent water); fresh leaf juice (Presssaft); powdered dried leaf in capsules
The dried basal rosette leaf is the official pharmacopeial drug described in the European Pharmacopoeia (Ph.Eur.), German Commission E, ESCOP, WHO, and EMA monographs. It is the part supported by the clinical evidence base for hepatobiliary, digestive, and hypolipidemic indications. The leaf contains the highest concentrations of the key bioactive caffeoylquinic acids (chlorogenic acid, cynarin), flavonoids (luteolin glycosides, scolymoside), and bitter sesquiterpene lactones (cynaropicrin). The leaf is distinct from the edible immature flower head consumed as food. Fresh leaf juice (Presssaft) is a traditional German preparation also covered by Commission E.
Fresh leaf juice (Presssaft)
Preferred: Stabilized fresh plant juice taken diluted in water; standardized to caffeoylquinic acid content
Traditional German preparation obtained by mechanically pressing fresh artichoke leaves. Listed in the German Commission E monograph. The expressed juice contains the water-soluble constituents in their native form. This preparation was historically important in German phytotherapy (Presssaft nach HAB) and is the basis for some commercial liquid preparations (e.g., Schoenenberger Artischockensaft). The juice must be stabilized (typically by pasteurization or addition of small amounts of ethanol) to prevent rapid enzymatic degradation.
Root
Preferred: Decoction (traditional use only; not standardized)
The root of Cynara scolymus has been used in some traditional Mediterranean and folk medicine systems as a diuretic and digestive tonic. It contains inulin (a prebiotic fructo-oligosaccharide) in significant quantities. However, the root is NOT the subject of modern pharmacopeial monographs and has not been evaluated in clinical trials. It is not recommended as a substitute for the leaf in therapeutic applications.
Key Constituents
Caffeoylquinic acids (phenolic acids / hydroxycinnamic acid derivatives)
The caffeoylquinic acids are considered the primary active constituents responsible for the choleretic, hepatoprotective, antioxidant, and hypolipidemic effects of artichoke leaf. They act through multiple mechanisms: stimulation of bile acid secretion by hepatocytes (choleresis), inhibition of de novo cholesterol biosynthesis via HMG-CoA reductase inhibition (demonstrated by Gebhardt 1997 in primary rat hepatocytes), protection of hepatocytes against oxidative damage (free radical scavenging and upregulation of glutathione), and inhibition of LDL oxidation. The European Pharmacopoeia uses chlorogenic acid content as the principal quality marker for Cynarae folium. The ongoing use of cynarin as a standardization marker in commercial products reflects historical convention rather than current understanding of which individual compound is most pharmacologically important in the whole extract.
Flavonoids
The flavonoid fraction, particularly luteolin and its glycosides, is now recognized as critically important for the hypolipidemic action of artichoke leaf. Gebhardt's landmark studies (1997, 2002) demonstrated that luteolin is the most potent individual compound from artichoke leaf for inhibiting cholesterol biosynthesis in cultured hepatocytes, with greater potency than cynarin or chlorogenic acid. The flavonoids also contribute significantly to the antioxidant, anti-inflammatory, and hepatoprotective activity of the whole extract. Scolymoside (luteolin-7-O-rutinoside) is highly bioavailable and is used as an additional quality marker in some pharmacopeial assays.
Sesquiterpene lactones (bitter principles)
The sesquiterpene lactones are essential for the digestive bitter action of artichoke leaf -- the 'bitter principle' that underlies its traditional and pharmacopeial use for dyspepsia and digestive complaints. Activation of bitter taste receptors (T2Rs) on the tongue triggers a reflex arc (the 'bitter reflex') that increases salivary flow, gastric acid secretion, pancreatic enzyme release, and bile production. Additionally, T2Rs in the gastrointestinal tract directly modulate gut motility and hormone secretion (CCK, GLP-1). Cynaropicrin is also the primary allergen responsible for contact dermatitis in artichoke handlers (occupational allergy) and the compound that underlies the Asteraceae allergy contraindication. The alpha-methylene-gamma-butyrolactone group common to many Asteraceae sesquiterpene lactones acts as a Michael acceptor, forming covalent bonds with nucleophilic thiol groups in skin proteins, leading to hapten formation and type IV hypersensitivity.
Polysaccharides (inulin and related fructans)
Inulin provides prebiotic support to gut microbiota, contributing to the gastrointestinal benefits of artichoke leaf preparations. While most standardized extracts focus on polyphenolic constituents, the inulin content of whole leaf preparations and fresh juice may contribute to digestive health benefits through gut microbiome modulation. This is particularly relevant to the observed benefits in IBS patients (Walker et al. 2001), where prebiotic effects on gut flora may complement the choleretic and spasmolytic actions.
Phytosterols and lipophilic compounds
The phytosterol and volatile oil constituents are minor contributors to the overall pharmacological profile of artichoke leaf. Taraxasterol adds to the anti-inflammatory effects, and phytosterols provide modest adjunctive cholesterol-lowering activity through intestinal cholesterol absorption competition. These constituents are of secondary importance compared to the caffeoylquinic acids, flavonoids, and sesquiterpene lactones.
Organic acids and minerals
Organic acids and minerals are minor contributors to the therapeutic profile. The potassium content supports the traditional diuretic indication and may contribute modestly to blood pressure management. These constituents are of supportive rather than primary importance.
Herbal Actions
The most well-documented and clinically established action of artichoke leaf. Choleretic (stimulates bile production by hepatocytes) and cholagogue (promotes bile release from the gallbladder). Kirchhoff et al. (1994) demonstrated a 127-152% increase in bile secretion over baseline within 30-60 minutes of intraduodenal administration of artichoke extract in a double-blind, placebo-controlled crossover study (n=20, p < 0.01 vs placebo). This action is the basis for the Commission E approval for dyspeptic complaints. The mechanism involves direct stimulation of hepatocyte bile acid synthesis and secretion by caffeoylquinic acids and bitter-receptor-mediated vagal reflexes triggered by cynaropicrin. Increased bile flow improves fat digestion and absorption, provides a vehicle for hepatic waste excretion, and supports intestinal motility.
[1, 2, 6, 11]Protects the liver from damage
Artichoke leaf extract protects hepatocytes against oxidative damage through multiple mechanisms: direct free radical scavenging by caffeoylquinic acids and flavonoids, enhancement of endogenous antioxidant defenses (glutathione, superoxide dismutase, catalase), inhibition of lipid peroxidation, and suppression of pro-inflammatory pathways (NF-kB inhibition by luteolin and cynaropicrin). Gebhardt (1997) demonstrated that artichoke leaf extract prevented carbon tetrachloride-induced toxicity in cultured rat hepatocytes and inhibited malondialdehyde (MDA) formation (a marker of lipid peroxidation). The hepatoprotective effect is complementary to the choleretic action: enhanced bile flow aids hepatic detoxification while antioxidant protection shields hepatocytes from endogenous and exogenous toxins. Clinical data supporting hepatoprotection includes the Rangboo et al. (2016) RCT showing significant reductions in ALT and AST in NAFLD patients receiving artichoke leaf extract.
[5, 6, 12, 14]Artichoke leaf extract reduces total cholesterol, LDL-cholesterol, and triglycerides through at least three complementary mechanisms: (1) Inhibition of de novo cholesterol biosynthesis -- Gebhardt (1997, 2002) showed that artichoke leaf extract and its constituent luteolin inhibit HMG-CoA reductase activity in primary hepatocyte cultures, the same enzymatic target as statin drugs, though through a different (indirect) mechanism. (2) Enhanced biliary cholesterol excretion -- increased bile flow promotes the excretion of cholesterol as bile acids. (3) Inhibition of LDL oxidation -- caffeoylquinic acids prevent the oxidative modification of LDL that contributes to atherosclerotic plaque formation. Sahebkar et al. (2018) meta-analysis of 9 RCTs (n=702) confirmed significant reductions: total cholesterol -17.6 mg/dL (p < 0.001), LDL-C -14.9 mg/dL (p = 0.011), triglycerides -9.2 mg/dL (p = 0.011).
[7, 8, 13, 14, 15]Artichoke leaf is one of the most important digestive bitters in European phytotherapy. The sesquiterpene lactone cynaropicrin activates bitter taste receptors (T2Rs) on the tongue, initiating the cephalic phase of digestion through vagal reflexes: increased salivary flow, gastric acid secretion, pancreatic enzyme release, and bile production. Additionally, T2R receptors in the gut epithelium directly stimulate release of gastrointestinal hormones (cholecystokinin/CCK, glucagon-like peptide-1/GLP-1) that coordinate digestive function. This bitter action is the traditional basis for artichoke leaf's use in digestive complaints and is the primary mechanism underlying the Commission E and ESCOP indications for dyspepsia. Hoffmann (2003) classifies artichoke as a key hepatobiliary bitter with a more specific liver-targeted action than simple aromatic bitters.
[1, 2, 4, 5]Prevents or slows oxidative damage to cells
Artichoke leaf extract demonstrates robust antioxidant activity in multiple assay systems (DPPH, ORAC, FRAP, ABTS) due to its high polyphenolic content, particularly chlorogenic acid, luteolin glycosides, and caffeic acid derivatives. The antioxidant activity is both direct (free radical scavenging and metal ion chelation) and indirect (upregulation of endogenous antioxidant enzymes including glutathione peroxidase, superoxide dismutase, and catalase). Inhibition of LDL oxidation is particularly relevant to cardiovascular protection, as oxidized LDL is a key driver of atherogenesis. In a clinical trial involving metabolic syndrome patients, artichoke leaf extract significantly improved serum total antioxidant capacity and reduced oxidative stress markers.
[6, 13, 14]Increases urine production and output
Mild aquaretic (water-excreting) diuretic action documented in traditional use and supported by the potassium content of the leaf. This is a traditional rather than primary clinical indication. The diuretic effect is gentle and not comparable to pharmaceutical diuretics. Commission E does not list diuretic as a primary indication, but it is noted in traditional European herbal practice (BHP, Hoffmann 2003). The mechanism likely involves potassium-mediated effects on renal sodium handling and possibly direct effects on renal tubular function.
[4, 5]Clinical and observational data support antiemetic activity of artichoke leaf extract. This is likely mediated by the choleretic action (improved bile flow aids fat digestion, reducing nausea associated with bile insufficiency and functional dyspepsia) and the prokinetic effects on gastric emptying mediated through bitter receptor activation and CCK release. Particularly effective for nausea associated with hepatobiliary dysfunction and post-prandial discomfort.
[6, 9]Mild antispasmodic effect on gastrointestinal smooth muscle, contributing to relief of cramping, bloating, and flatulence. Mechanism involves direct relaxation of smooth muscle (possibly through calcium channel modulation) and indirect effects via improved bile flow and digestive function. The spasmolytic activity complements the bitter digestive action in the overall management of functional dyspepsia and irritable bowel syndrome. Less potent than dedicated antispasmodic herbs such as peppermint or chamomile.
[5, 6, 9]The inulin content of artichoke leaf (particularly in whole-leaf and fresh juice preparations) provides prebiotic substrate for beneficial colonic bacteria (Bifidobacterium, Lactobacillus spp.). Fermentation of inulin by colonic bacteria produces short-chain fatty acids (SCFAs) including butyrate, which nourishes colonocytes and supports intestinal barrier integrity. This prebiotic action may contribute to the beneficial effects observed in IBS patients. Note that highly purified standardized extracts may contain less inulin than whole-leaf preparations.
[5]Therapeutic Indications
Hepatobiliary System
Dyspepsia (functional, non-ulcer dyspepsia)
This is the primary pharmacopeial indication for artichoke leaf, supported by the German Commission E positive monograph (1990), ESCOP monograph (2003), WHO monograph, and EMA community herbal monograph. The Commission E approved artichoke leaf for 'dyspeptic problems.' ESCOP expands this to 'digestive disorders, e.g., stomach ache, nausea, vomiting, feeling of fullness, flatulence.' The evidence base includes the Kirchhoff et al. (1994) choleresis study demonstrating 127-152% increases in bile secretion, numerous post-marketing surveillance studies, and the Walker et al. (2001) study showing significant reduction in dyspeptic symptoms. The mechanism involves enhanced bile production and flow (improving fat digestion), bitter-receptor-mediated stimulation of digestive secretions, and mild spasmolytic effects on GI smooth muscle.
[1, 2, 3, 6, 9, 11]Hepatoprotection and liver support (general)
Artichoke leaf extract protects hepatocytes through multiple mechanisms: antioxidant free radical scavenging, enhanced glutathione levels, inhibition of lipid peroxidation, enhanced bile-mediated hepatic detoxification, and suppression of pro-inflammatory pathways. Gebhardt (1997) demonstrated dose-dependent hepatoprotective effects in cultured rat hepatocytes exposed to tert-butyl hydroperoxide (oxidative stress model). Rangboo et al. (2016) RCT in NAFLD patients showed significant reductions in hepatic enzymes ALT and AST with artichoke leaf extract supplementation over 2 months. Clinical application includes support during hepatic steatosis (fatty liver), exposure to hepatotoxic substances, alcohol-related liver stress, and general liver tonic therapy.
[5, 6, 12, 14]Bile insufficiency and biliary dyskinesia
Artichoke leaf is specifically indicated when dyspeptic symptoms arise from inadequate bile production or impaired bile flow (biliary dyskinesia). The choleretic action directly addresses this pathophysiology. Kirchhoff et al. (1994) concluded that artichoke extract 'can be recommended for the treatment of dyspepsia, especially when the cause may be attributed to dyskinesia of the bile ducts or disorder in the assimilation of fat.' Clinical presentations include post-prandial bloating and discomfort after fatty meals, pale or fatty stools (steatorrhea), nausea, and right upper quadrant heaviness. Contraindicated in bile DUCT OBSTRUCTION (e.g., gallstones obstructing the common bile duct), where stimulation of bile flow would be dangerous.
[1, 2, 4, 11]Non-alcoholic fatty liver disease (NAFLD/MAFLD)
Emerging clinical evidence supports artichoke leaf extract for NAFLD. Rangboo et al. (2016) RCT demonstrated significant reductions in liver enzymes (ALT, AST) and improvements in liver ultrasound findings in NAFLD patients supplemented with artichoke leaf extract for 2 months. A systematic review and meta-analysis (Moradi et al. 2021) of artichoke for fatty liver found consistent benefits. Mechanisms include enhanced hepatic lipid metabolism via bile acid excretion, inhibition of hepatic de novo lipogenesis, antioxidant protection against lipid peroxidation, and anti-inflammatory effects. This is a growing area of clinical research interest.
[5, 12, 13]Cardiovascular System
Hyperlipidemia and hypercholesterolemia
Multiple RCTs and a comprehensive meta-analysis support artichoke leaf extract for lowering total cholesterol, LDL-cholesterol, and triglycerides. Englisch et al. (2000) conducted a pivotal RCT: 143 patients with total cholesterol > 7.3 mmol/L received 1800 mg/day standardized artichoke leaf extract or placebo for 6 weeks. Results showed 18.5% reduction in total cholesterol and 22.9% reduction in LDL-C in the active group vs 8.6% and 6.3% in placebo (p < 0.001). Bundy et al. (2008) RCT (n=75, 12 weeks) demonstrated a 4.2% reduction in total cholesterol with 1280 mg/day artichoke leaf extract (p = 0.025 vs placebo). Sahebkar et al. (2018) meta-analysis of 9 RCTs (n=702) confirmed: total cholesterol -17.6 mg/dL (p < 0.001), LDL-C -14.9 mg/dL (p = 0.011), triglycerides -9.2 mg/dL (p = 0.011). ESCOP includes mild to moderate hyperlipidemia as an adjunctive indication. The magnitude of cholesterol lowering is moderate and artichoke leaf is best considered adjunctive to dietary and lifestyle interventions, or as an alternative for patients who cannot tolerate statins.
[2, 7, 8, 13, 15]Metabolic syndrome (adjunctive)
Artichoke leaf extract addresses multiple components of metabolic syndrome simultaneously: hypolipidemic effects on cholesterol and triglycerides, antioxidant protection against oxidative stress, emerging evidence for modest blood glucose and insulin regulation, and possible blood pressure-lowering effects. Clinical trials in metabolic syndrome patients have demonstrated improvements in lipid profiles, antioxidant status, and insulin sensitivity markers. The multi-target profile makes artichoke leaf a rational adjunctive botanical for metabolic syndrome, though it should not replace first-line interventions (diet, exercise, weight management).
[5, 13]Atherosclerosis prevention (adjunctive)
The combination of LDL-cholesterol lowering, inhibition of LDL oxidation (a key step in atherogenesis), antioxidant protection, and mild anti-inflammatory activity provides a multi-mechanistic rationale for artichoke leaf extract in atherosclerosis prevention. However, no long-term cardiovascular outcome trials have been conducted with artichoke leaf extract specifically. The evidence is based on surrogate markers (lipid levels, oxidized LDL) and mechanistic studies rather than hard cardiovascular endpoints.
[6, 13]gastrointestinal
Irritable bowel syndrome (IBS)
Walker et al. (2001) conducted a post-marketing surveillance study identifying a sub-group of 279 IBS patients who received artichoke leaf extract for 6 weeks. Significant reductions in IBS symptom severity were observed: 26.4% reduction in IBS symptom incidence, with significant improvements in abdominal pain, cramping, bloating, flatulence, and constipation. 96% of patients rated artichoke leaf extract as 'equal to or better than' previous therapies. Bundy et al. (2004) subsequently published a subset analysis confirming improvements in IBS symptoms and quality of life. The mechanisms likely involve choleretic effects (improving fat digestion and reducing bloating), bitter-receptor-mediated digestive stimulation, mild spasmolytic activity, and prebiotic effects of inulin on gut microbiota. While not a placebo-controlled RCT, the consistent clinical observations across large patient numbers support this indication.
[5, 9, 10]Nausea and vomiting (functional, non-specific)
Traditional use as an antiemetic for nausea associated with hepatobiliary dysfunction, fatty food intolerance, and functional dyspepsia. The antiemetic action is attributed to improved bile flow (reducing nausea from bile insufficiency and fat maldigestion) and prokinetic effects on gastric emptying. ESCOP lists nausea among the symptoms improved by artichoke leaf extract. More effective for nausea of digestive/hepatobiliary origin than for motion sickness or chemotherapy-induced nausea.
[2, 4, 6]Bloating, flatulence, and abdominal discomfort
Relief of bloating, flatulence, and abdominal discomfort is one of the primary indications in the EMA traditional use monograph and ESCOP monograph. These symptoms are frequently associated with inadequate bile production, poor fat digestion, and intestinal gas production from undigested food substrates. Artichoke leaf addresses the root cause (bile insufficiency) while also providing symptomatic relief through mild spasmolytic and carminative effects. Large-scale post-marketing surveillance studies consistently report improvement in these symptoms.
[1, 2, 3, 9]Endocrine System
Blood glucose regulation (adjunctive)
Emerging evidence from clinical trials and a systematic review suggests that artichoke leaf extract may have modest effects on blood glucose and insulin sensitivity. Chlorogenic acid inhibits glucose-6-phosphate translocase, and dicaffeoylquinic acid derivatives modulate alpha-glucosidase activity, both of which can reduce post-prandial glycemic excursions. A clinical trial in overweight subjects with impaired fasting glucose showed significant improvements in blood glucose, insulin levels, and HOMA-IR with artichoke extract supplementation. However, the evidence base is smaller than for the lipid-lowering indication and requires confirmation in larger trials.
[5, 13]Urinary System
Mild fluid retention (traditional diuretic)
Traditional European use of artichoke leaf as a mild diuretic (aquaretic) for water retention and as a depurative (blood-cleansing) agent. The potassium content and possible direct effects on renal tubular function may contribute. This is a traditional rather than evidence-based indication. Artichoke leaf is not a potent diuretic and should not be relied upon for clinically significant edema or congestive states.
[4, 5]Energetics
Temperature
cool
Moisture
dry
Taste
Tissue States
hot/excitation, damp/stagnation, damp/relaxation
In Western herbal energetics, artichoke leaf is classified as cool and moderately drying, with a prominently bitter taste and a subtle salty quality. The cooling nature makes it well-suited for conditions with excess heat, particularly in the liver and digestive system -- what traditional herbalists describe as 'liver heat' manifesting as irritability, headache, skin eruptions, and inflammatory digestive conditions. The drying quality addresses damp, stagnant conditions in the hepatobiliary system: sluggish bile flow, poor fat digestion, metabolic congestion, and phlegmatic accumulations. In TCM terms, artichoke leaf is bitter and slightly cold, entering the Liver, Gallbladder, Spleen, and Stomach channels. It clears Liver heat, resolves Damp-Heat, moves Liver Qi, and promotes the smooth flow of bile. This energetic profile makes it particularly indicated for constitutions showing signs of hepatic congestion, metabolic sluggishness, and digestive stagnation with heat signs. It is less appropriate for cold, deficient constitutions with weak digestive fire, where warming bitters (like gentian or angelica) might be preferred. Artichoke leaf addresses hot/excited tissue states (liver inflammation, irritation), damp/stagnant states (biliary sluggishness, metabolic congestion, hyperlipidemia), and damp/relaxed states (atonic digestion with poor bile output). CAVEAT: Herbal energetics are interpretive frameworks within Western herbalism and TCM, not standardized across all practitioners.
Traditional Uses
Ancient Greek and Roman medicine (Classical Antiquity)
- Consumed as a food and digestive aid since at least the 4th century BCE; the wild cardoon ancestor was cultivated in Sicily by the ancient Greeks, who called it 'kaktos'
- Dioscorides (De Materia Medica, 1st century CE) described the plant under the name 'skolymos' and recommended the root juice for foul-smelling perspiration and the plant for digestive and urinary complaints
- Pliny the Elder (Naturalis Historia, 77 CE) described the artichoke under the name 'carduus' as a luxury food from Carthage and Cordoba, praising its digestive virtues and noting its diuretic properties
- Used as a hepatic and biliary remedy in Greco-Roman medicine, valued for improving bile flow and digestion
- Traditional use as a diuretic and for urinary complaints in classical medicine
"Dioscorides (De Materia Medica, Book 3, Chapter 14) identifies the plant with the term 'skolymos' used by Hesiod, grouping it with a class of thistles (kinara). Pliny the Elder (Naturalis Historia, 77 CE) refers to it as 'carduus' and describes it as among the most prized and expensive of foods, praising its digestive virtues. The cultivation and medicinal use of artichoke in the ancient Mediterranean represents one of the oldest documented traditions of using this plant for hepatobiliary and digestive support."
Renaissance and early modern European medicine (15th-18th centuries)
- Reintroduced to European cultivation from the Arab world via Sicily and southern Italy in the late 15th century
- Catherine de' Medici reportedly brought artichokes to France in the 16th century, where they became valued both as food and medicine
- Used extensively in Renaissance Italian and French herbalism as a hepatic remedy, digestive tonic, and choleretic
- Employed as a diuretic and 'blood-purifying' (depurative) agent in European folk medicine
- Applied topically as a poultice for liver complaints in some European folk traditions
"The artichoke's re-emergence in Renaissance European cuisine and medicine is well documented. It traveled from the Arab world (where it had been cultivated since the 9th century) to southern Italy by the late 1400s, and from there spread to France and the rest of Europe. By the 16th century, it was firmly established in European pharmacopeias as a hepatic and digestive remedy."
Traditional German phytotherapy (19th-20th centuries)
- Fresh pressed juice of artichoke leaves (Presssaft) used as a choleretic and hepatoprotective remedy
- Treatment of dyspepsia, flatulence, nausea, and abdominal discomfort associated with hepatobiliary dysfunction
- Adjunctive therapy for hypercholesterolemia and atherosclerosis prevention
- Used in combination with other hepatobiliary herbs (milk thistle, dandelion root, boldo) in bitter tonics and digestive elixirs
- Commission E positive monograph (1990) confirmed traditional use for dyspeptic problems
"German phytotherapy has been at the forefront of modern scientific investigation into artichoke leaf since the early 20th century. The isolation of cynarin in the 1930s-1950s by German researchers spurred systematic pharmacological investigation. The German Commission E issued a positive monograph for artichoke leaf in 1990, validating its traditional use for dyspeptic complaints. Fresh plant juice preparations (Presssaft) following the Schoenenberger method became a distinctive feature of German herbal practice. Germany remains the largest European market for artichoke leaf preparations."
Traditional Mediterranean folk medicine
- Leaf decoction for liver and gallbladder complaints throughout Italy, Spain, and southern France
- Used as a bitter aperitif before meals to stimulate appetite and digestion
- Traditional remedy for jaundice and hepatitis in Mediterranean folk practice
- Leaf preparations used as a diuretic and for urinary tract support
- Root decoction used for fluid retention and as a general tonic in Sicilian and Sardinian folk medicine
- Topical application of crushed leaves for skin conditions and wound healing in North African folk medicine
"Throughout the Mediterranean basin, artichoke has been a staple of both culinary and medicinal traditions for centuries. Italian, Spanish, French, Tunisian, and Moroccan folk medicine all include artichoke leaf preparations for liver and digestive complaints. The Italian practice of drinking bitter artichoke-based aperitifs (such as Cynar liqueur, created in 1952) reflects the deep cultural integration of the plant's digestive properties."
Unani (Greco-Islamic) medicine
- Known as 'Kangar' or 'Harshuf' in Unani pharmacopeias
- Used to resolve liver obstructions and promote bile flow
- Treatment of jaundice, hepatic congestion, and splenic enlargement
- Applied as a digestive and appetizer to stimulate gastric function
- Considered to have a cold and dry temperament (mizaj), used to counter hot liver conditions
"Artichoke entered the Islamic medical tradition during the medieval period, when Arab scholars translated and expanded upon Greco-Roman medical texts. Artichoke cultivation spread throughout the Islamic world from the 9th century onward, with the plant documented in the pharmacopeias of Ibn Sina (Avicenna), Al-Razi (Rhazes), and other Unani scholars as a hepatic and digestive remedy with a cold, dry temperament."
[5]
Modern Research
Artichoke leaf extract for hypercholesterolemia (Englisch et al. 2000)
Landmark randomized, double-blind, placebo-controlled trial evaluating the cholesterol-lowering efficacy of standardized artichoke leaf extract (1800 mg/day of a 25-35:1 aqueous extract) in 143 patients with total cholesterol > 7.3 mmol/L over 6 weeks.
Findings: Total cholesterol decreased by 18.5% in the artichoke leaf extract group vs 8.6% in the placebo group (p < 0.001). LDL-cholesterol decreased by 22.9% vs 6.3% in placebo (p < 0.001). The magnitude of total and LDL cholesterol reduction was comparable to that reported for some statin drugs (Wolffenbuttel et al. 1998 comparison). No significant adverse events were reported. The study established artichoke leaf extract as a clinically relevant hypolipidemic botanical agent.
Limitations: 6-week duration limits assessment of long-term efficacy and safety. Single German population. High baseline cholesterol (mean 7.74 mmol/L) means results may not extrapolate to mild hypercholesterolemia. Specific commercial extract tested (Valverde Artischocke); results may not generalize to all artichoke leaf preparations.
[7]
Artichoke leaf extract for mild hypercholesterolemia (Bundy et al. 2008)
Randomized, double-blind, placebo-controlled trial of artichoke leaf extract (1280 mg/day) in 75 otherwise healthy adults with mild to moderate hypercholesterolemia (total cholesterol 6.0-8.0 mmol/L) over 12 weeks. Conducted at the Hugh Sinclair Unit of Human Nutrition, University of Reading, UK.
Findings: Total plasma cholesterol decreased by 4.2% in the artichoke leaf extract group (from 7.16 to 6.86 mmol/L) while increasing by 1.9% in the placebo group, with the between-group difference being statistically significant (p = 0.025). No significant differences were observed for LDL-cholesterol, HDL-cholesterol, or triglycerides individually. The modest magnitude of response was attributed to the relatively healthy status of the study population and the lower daily dose compared to the Englisch et al. (2000) study.
Limitations: Modest effect size on total cholesterol only, with no significant effects on LDL or triglycerides. Lower dose (1280 mg vs 1800 mg in Englisch study). Relatively small sample size (n=75). UK population with mild hypercholesterolemia may have less room for improvement than the Englisch study population with higher baseline cholesterol.
[8]
Artichoke leaf extract and irritable bowel syndrome (Walker et al. 2001)
Large-scale post-marketing surveillance study of artichoke leaf extract (ALE) for dyspeptic complaints, with a pre-planned sub-group analysis of 279 patients meeting criteria for IBS. Patients received 320-640 mg ALE capsules (standardized extract) for 6 weeks.
Findings: In the IBS sub-group, a 26.4% reduction in IBS symptom incidence was observed over 6 weeks. Significant improvements were documented in abdominal pain, cramping, bloating, flatulence, and constipation. 96% of patients rated ALE as 'equal to or better than' previous therapies for their symptoms. The tolerability was rated as very good. Overall quality of life improved significantly. In the broader dyspepsia population (n=553), symptom scores decreased by approximately 70%.
Limitations: Post-marketing surveillance design (not placebo-controlled). Open-label. No randomization. Expectation and placebo effects cannot be excluded. However, the large sample size, consistent symptom improvement across multiple parameters, and favorable tolerability profile provide meaningful real-world clinical data. The authors recommended further placebo-controlled studies.
[9]
Artichoke leaf extract and IBS with concomitant dyspepsia: subset analysis (Bundy et al. 2004)
Subset analysis from the Walker et al. (2001) post-marketing surveillance study, focusing on patients with IBS who also suffered from concomitant dyspepsia. This analysis examined quality of life outcomes alongside symptom data.
Findings: Patients with concurrent IBS and dyspepsia showed significant reductions in the severity of all IBS symptoms and improvements in quality of life measures. The authors concluded that artichoke leaf extract is beneficial for patients with the common clinical overlap of IBS and functional dyspepsia, where hepatobiliary dysfunction may be a contributing factor.
Limitations: Same limitations as the parent study (open-label, not placebo-controlled). Subset analysis further reduces sample size. Self-reported outcomes.
[10]
Choleretic effect of artichoke extract: placebo-controlled study (Kirchhoff et al. 1994)
Randomized, placebo-controlled, double-blind crossover study measuring the acute choleretic effect of artichoke extract administered intraduodenally in 20 healthy volunteers. Bile secretion was quantified using multi-channel duodenal aspiration probes.
Findings: Artichoke extract (1.92 g administered intraduodenally) produced dramatic increases in bile secretion: 127.3% increase at 30 minutes, 151.5% increase at 60 minutes, and 94.3% increase at 120 minutes, all relative to baseline values. The differences versus placebo were statistically significant (p < 0.01 at 30 and 60 minutes; p < 0.05 at 120 and 150 minutes). No adverse effects or laboratory abnormalities were observed. This study provided the most direct clinical evidence for the choleretic mechanism underlying the Commission E indication.
Limitations: Small sample size (n=20). Intraduodenal administration bypasses oral and gastric processing; the magnitude of choleresis after oral ingestion may differ. Single-dose acute study. Healthy volunteers rather than patients with hepatobiliary dysfunction. However, the crossover design and objective bile measurement provide strong mechanistic evidence.
[11]
Hepatoprotective mechanism of artichoke leaf extract (Gebhardt 1997)
In vitro study examining the hepatoprotective and cholesterol biosynthesis-inhibiting effects of artichoke leaf extract in primary cultured rat hepatocytes. A landmark mechanistic study that elucidated key pharmacological pathways.
Findings: Artichoke leaf extract demonstrated dose-dependent protection of hepatocytes against oxidative damage induced by tert-butyl hydroperoxide (t-BHP). The extract inhibited malondialdehyde (MDA) formation, a marker of lipid peroxidation, indicating antioxidant hepatoprotection. Additionally, artichoke leaf extract inhibited cholesterol biosynthesis from 14C-acetate in hepatocyte cultures. When 14C-mevalonate was used as the precursor (bypassing HMG-CoA reductase), the inhibition was largely abolished, indicating that the primary target of cholesterol biosynthesis inhibition is at or before the HMG-CoA reductase step -- the same enzymatic step targeted by statin drugs.
Limitations: In vitro study in rat hepatocytes; results may not directly translate to human hepatic function in vivo. Crude extract used; specific compounds responsible were identified in subsequent work (Gebhardt 2002 identified luteolin as the most potent cholesterol-inhibiting compound). No dose-response data at clinically relevant plasma concentrations.
[14]
Luteolin as the key cholesterol biosynthesis inhibitor (Gebhardt 2002)
Follow-up in vitro study by Gebhardt testing individual purified constituents of artichoke leaf extract for cholesterol biosynthesis inhibition in HepG2 human hepatocyte cell lines.
Findings: Among the individual purified constituents tested (chlorogenic acid, cynarin, luteolin, cynaroside/luteolin-7-O-glucoside, caffeic acid), luteolin (the flavonoid aglycone) was identified as the MOST POTENT inhibitor of de novo cholesterol biosynthesis. The inhibition by luteolin was concentration-dependent and was mediated indirectly through HMG-CoA reductase. Cynarin and chlorogenic acid showed weaker cholesterol synthesis-inhibiting activity than luteolin. This study reframed understanding of which constituent classes drive the hypolipidemic effect of artichoke leaf, elevating the importance of the flavonoid fraction alongside the historically emphasized caffeoylquinic acids.
Limitations: In vitro study in HepG2 cells. Individual compound testing may not reflect the synergistic effects present in the whole extract. Bioavailability of luteolin from oral artichoke leaf preparations needs consideration -- luteolin glycosides must be hydrolyzed to release the active aglycone. Clinical translation from in vitro data requires caution.
[15]
Lipid-lowering activity of artichoke extracts: systematic review and meta-analysis (Sahebkar et al. 2018)
Systematic review and meta-analysis of all available randomized controlled trials evaluating the effects of artichoke extract supplementation on plasma lipid concentrations. Databases searched: PubMed-Medline, Scopus, Web of Science, Google Scholar through March 2017.
Findings: Meta-analysis of 9 RCTs (n=702) demonstrated significant reductions in: total cholesterol (WMD: -17.6 mg/dL, 95% CI: -22.0 to -13.3, p < 0.001), LDL-cholesterol (WMD: -14.9 mg/dL, 95% CI: -20.4 to -9.5, p = 0.011), and triglycerides (WMD: -9.2 mg/dL, 95% CI: -16.2 to -2.1, p = 0.011). No significant effect on HDL-cholesterol was observed (WMD: 1.0 mg/dL, p = 0.333). The authors concluded that artichoke extract supplementation is associated with clinically meaningful reductions in total cholesterol, LDL-C, and triglycerides, and may be a useful adjunct to lipid-lowering therapy.
Limitations: Heterogeneity in artichoke preparations, dosages, and treatment durations across included trials. Most trials were of short to moderate duration (6-12 weeks). Risk of publication bias. Insufficient data for subgroup analyses by dose or preparation type. Quality of some included trials was moderate.
[13]
Artichoke leaf extract in non-alcoholic fatty liver disease (Rangboo et al. 2016)
Randomized, double-blind, placebo-controlled trial evaluating artichoke leaf extract (2700 mg/day) in patients with non-alcoholic fatty liver disease (NAFLD) over 2 months.
Findings: Artichoke leaf extract supplementation resulted in significant reductions in hepatic enzymes: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) both decreased significantly in the active group compared to placebo. Improvements in liver ultrasound findings were also observed. The results provide clinical evidence for the hepatoprotective effects of artichoke leaf extract in NAFLD patients.
Limitations: Relatively short duration (2 months). Moderate sample size. Ultrasound assessment of fatty liver is operator-dependent and less precise than MRI-based techniques. Specific to NAFLD population. Requires replication in larger, longer-term trials.
[12]
Artichoke leaf extract: overview of effects on lipid metabolism, liver, and GI tract (Kraft 1997)
Comprehensive narrative review of the pharmacological and clinical evidence for artichoke leaf extract, covering effects on lipid metabolism, liver protection, choleresis, and gastrointestinal function. Reviewed the German clinical literature and Commission E evidence base.
Findings: Documented antioxidative, hepatoprotective, choleretic, and anti-cholestatic effects in molecular, cellular, and in vivo test systems. Confirmed inhibition of cholesterol biosynthesis and LDL oxidation. Reviewed clinical data supporting lipid-lowering, antiemetic, spasmolytic, choleretic, and carminative effects with good tolerance and low incidence of side effects. Identified chlorogenic acid (not cynarin) as the most abundant native caffeoylquinic acid in artichoke leaf, correcting earlier overemphasis on cynarin.
Limitations: Narrative rather than systematic review. Published before the major RCTs (Englisch 2000, Bundy 2008). Predominantly reviewed German-language literature.
[6]
Preparations & Dosage
Standardized Extract
Strength: DER 4-7:1 (water extraction) or DER 25-35:1 (concentrated aqueous extract). Standardized to >= 2.5% cynarin or >= 13-18% caffeoylquinic acids (expressed as chlorogenic acid) depending on manufacturer.
Commercially prepared standardized dry extracts are the preparation form used in the majority of clinical trials and are the recommended form for therapeutic use. The most common standardization markers are: (a) caffeoylquinic acid content, typically expressed as chlorogenic acid (Ph.Eur. standard: >= 0.8% chlorogenic acid), or (b) cynarin content (commonly 2.5-5% cynarin). Clinical trial products include Valverde Artischocke (Englisch et al. 2000), Hepar-SL forte (Kirchhoff et al. 1994), and Cynara-SL. Typical drug-extract ratio (DER): 4-7:1, extraction solvent water; or DER 25-35:1 aqueous extract (high-concentrate).
Standardized dry extract (DER 4-7:1): 600-1200 mg daily in divided doses. High-concentrate extract (DER 25-35:1): 500-1800 mg daily in divided doses. Clinical trial doses: 1280-1800 mg/day of standardized extract (Bundy 2008: 1280 mg; Englisch 2000: 1800 mg of 25-35:1 extract). For NAFLD: 2700 mg/day (Rangboo 2016).
Two to three times daily, preferably taken before or with meals to enhance digestive effects
Clinical trials have used 6-12 weeks of treatment. May be used long-term for chronic conditions (hyperlipidemia, recurrent dyspepsia). Reassess therapeutic need periodically.
Limited pediatric data. EMA monograph recommends use only in adults and adolescents over 12 years. Adolescents 12-18: adult dose under practitioner guidance.
Standardized extracts are the most clinically validated preparation form and provide the most consistent and reproducible dosing. The clinical evidence supporting cholesterol-lowering and hepatoprotective effects is primarily based on standardized extract preparations. Products should specify DER, extraction solvent, and marker compound content. Third-party testing is recommended to verify compliance with label claims. Note that cynarin content in standardized extracts is partly an artifact of processing (isomerization of 1,5-di-O-caffeoylquinic acid during extraction), which is not a problem for clinical use but should be understood when interpreting standardization claims.
Capsule / Powder
Strength: Crude powder: 500 mg per capsule. Extract capsules: 300-600 mg standardized extract per capsule.
Dried artichoke leaf, finely powdered, filled into vegetarian or gelatin capsules. Alternatively, standardized dry extract powder encapsulated. Powdered whole leaf provides the complete phytochemical profile (including inulin and fiber) but at lower concentrations of active compounds compared to concentrated extracts.
Powdered dried leaf: 1.5-3 g daily in divided doses (Commission E dosage). Standardized extract capsules: 300-600 mg per capsule, 2-3 capsules daily (600-1800 mg total daily).
Two to three times daily, with or before meals
May be used long-term. Reassess periodically.
Not recommended for children under 12. Adolescents: adult dose under supervision.
Capsules of powdered whole leaf are convenient for general digestive support but provide lower concentrations of active compounds than concentrated extracts. For the therapeutic indications supported by clinical trial evidence (hyperlipidemia, NAFLD), standardized extract capsules are preferred. Product labeling should distinguish between crude leaf powder and concentrated extract.
Tincture
Strength: 1:5, 25-45% ethanol (dried leaf). BHP standard: 1:5, 40% ethanol.
Dried artichoke leaf macerated in hydroalcoholic solvent. Standard ratio 1:5 in 25-45% ethanol. Macerate for 2-4 weeks with regular agitation. Press and filter. The moderate alcohol content extracts both the hydrophilic caffeoylquinic acids and flavonoids and the lipophilic sesquiterpene lactones (cynaropicrin). The tincture will be characteristically bitter.
2-5 mL (40-100 drops) three times daily, taken in a small amount of water before or with meals. BHP recommends 1:5 tincture, 40% ethanol, dose 2-6 mL three times daily.
Two to three times daily, preferably before meals to stimulate digestive function
May be used long-term for chronic conditions. Short courses (2-4 weeks) for acute dyspepsia.
Not recommended for children due to alcohol content
Tincture is a convenient liquid preparation for clinical herbalists that allows flexible dosing. The bitter taste of the tincture is considered therapeutically important -- bitterness activates T2R receptors and initiates the cephalic digestive reflex. Diluting in too much liquid or encapsulating the tincture (to avoid the taste) may reduce this reflex contribution. Tinctures are the traditional preparation form in Western clinical herbalism and are particularly suited for combination with other hepatobiliary and digestive herbs (e.g., dandelion root, milk thistle, gentian, burdock root). Note: tinctures have not been the subject of major clinical trials; the clinical evidence base is primarily for standardized dry extracts.
Infusion (Tea)
Strength: 1-2 g dried leaf per 150-200 mL water. Daily dose: 6 g dried leaf (Commission E).
Pour 150-200 mL of boiling water over 1-2 g of dried, cut or coarsely ground artichoke leaf. Steep for 10-15 minutes (covered to retain volatile constituents). Strain and drink. The infusion will be pale greenish-yellow with a pronouncedly bitter taste.
1-2 g of dried leaf per cup (150-200 mL). Drink 1 cup three times daily before or with meals. Total daily dose: 3-6 g dried leaf. Commission E: 6 g daily.
Three times daily, before or with meals
May be used long-term as a daily digestive bitter tea
Not recommended for children under 12. Adolescents: 1 cup once or twice daily.
Infusion is the simplest preparation method and is covered by the EMA traditional use monograph and Commission E. The hot water extraction primarily yields the hydrophilic caffeoylquinic acids, flavonoid glycosides, and some inulin. Lipophilic sesquiterpene lactones are less efficiently extracted by water alone. The strongly bitter taste should be accepted as therapeutically relevant rather than disguised with sweeteners, as the bitter reflex contributes to digestive stimulation. The infusion can be combined with more palatable herbs (peppermint, fennel, lemon balm) for improved flavor if needed.
fresh-plant-juice
Strength: Fresh pressed juice; DER approximately 15-30:1 relative to fresh leaf weight (due to water content of fresh leaves)
Fresh artichoke leaves are mechanically pressed to obtain the expressed juice (Presssaft). The juice is stabilized by brief pasteurization or addition of small amounts of ethanol to prevent enzymatic degradation. This preparation represents the traditional German Presssaft method (Schoenenberger). The juice contains the water-soluble constituents in their native proportions, including chlorogenic acid (as the dominant caffeoylquinic acid, since cynarin formation requires drying/heating), flavonoid glycosides, and inulin.
10-30 mL fresh plant juice three times daily, diluted in a small amount of water. Take before or with meals.
Three times daily before meals
Typically used in 4-6 week courses, but may be continued long-term
Not recommended for children under 12
Fresh plant juice is listed in the German Commission E monograph and represents a traditional German pharmaceutical preparation. It has the advantage of containing the native (non-isomerized) phytochemical profile with chlorogenic acid as the dominant caffeoylquinic acid. The juice is more palatable than dried leaf infusions due to dilution and natural sugars. Schoenenberger Artischockensaft is the best-known commercial preparation. Fresh juice preparations require refrigeration and have a limited shelf life (typically 6-12 months when stabilized). This preparation is predominantly available in Germany and German-speaking countries.
Safety & Interactions
Class 1
Can be safely consumed when used appropriately (AHPA Botanical Safety Handbook)
Contraindications
The choleretic/cholagogue action of artichoke leaf stimulates bile production and flow. In the presence of bile duct obstruction (e.g., gallstones obstructing the common bile duct), increased bile pressure against an obstruction can cause severe biliary colic, jaundice, cholangitis, or pancreatitis. This is the most important contraindication and is stated in the Commission E monograph, ESCOP monograph, and EMA monograph. Patients with known gallstones should use artichoke leaf only under medical supervision and only if bile duct patency has been confirmed.
Artichoke is a member of the Asteraceae (Compositae) family and contains sesquiterpene lactones (primarily cynaropicrin) that are known contact allergens. Individuals with confirmed allergy to Asteraceae plants (ragweed, chrysanthemums, daisies, marigolds, chamomile, echinacea, etc.) are at increased risk of allergic reactions to artichoke leaf preparations. Reactions may include contact dermatitis, urticaria, or rarely anaphylaxis. Occupational contact dermatitis from artichoke handling is well-documented in agricultural workers. The alpha-methylene-gamma-butyrolactone group of cynaropicrin acts as a hapten, forming covalent bonds with skin proteins and triggering type IV (delayed) hypersensitivity reactions.
Previous allergic or hypersensitivity reaction to artichoke leaf extract or any component of the preparation is a contraindication. Cross-reactivity with other Asteraceae species is possible due to shared sesquiterpene lactone structures.
Drug Interactions
| Drug / Class | Severity | Mechanism |
|---|---|---|
| Anticoagulants (warfarin) and antiplatelet agents (Anticoagulants and antiplatelets) | theoretical | Artichoke leaf has no documented direct anticoagulant or antiplatelet activity. However, enhanced bile flow may theoretically increase absorption of fat-soluble vitamin K, potentially affecting warfarin dosing. This interaction has not been confirmed clinically and is considered theoretical. |
| Statins (atorvastatin, simvastatin, rosuvastatin, etc.) (HMG-CoA reductase inhibitors) | theoretical | Artichoke leaf extract inhibits cholesterol biosynthesis via indirect HMG-CoA reductase inhibition (Gebhardt 1997, 2002). Concurrent use with statins could theoretically produce additive cholesterol-lowering effects. This may be desirable clinically (allowing lower statin doses) but should be monitored. |
| Antidiabetic medications (metformin, sulfonylureas, insulin) (Hypoglycemic agents) | theoretical | Chlorogenic acid and other artichoke leaf constituents may modestly reduce blood glucose levels through inhibition of glucose-6-phosphate translocase and alpha-glucosidase. Additive hypoglycemia is theoretically possible when combined with pharmacological antidiabetic agents. |
| Antihypertensive medications (Antihypertensives) | theoretical | Some evidence suggests artichoke leaf extract may have mild blood pressure-lowering effects. Combined use with antihypertensive medications could theoretically produce additive hypotension. |
| Colchicine (Anti-gout agents) | theoretical | In vitro evidence suggests artichoke leaf extract may inhibit CYP2B6 and potentially affect P-glycoprotein transport, which could alter colchicine clearance. Colchicine has a narrow therapeutic index. |
Pregnancy & Lactation
Pregnancy
insufficient data
Lactation
insufficient data
There is insufficient clinical safety data for the use of artichoke leaf extract during pregnancy and lactation. No controlled studies in pregnant or breastfeeding women have been conducted. The EMA monograph states that use during pregnancy and lactation is not recommended due to lack of data. Traditional use does not specifically contraindicate artichoke in pregnancy, but the choleretic, bitter, and hormonal-modulating properties raise theoretical concerns. Artichoke consumption as a FOOD (edible flower heads) in normal dietary amounts during pregnancy is considered safe and has a long history. However, therapeutic doses of concentrated leaf EXTRACT are a different consideration. As a precautionary measure, medicinal doses of artichoke leaf preparations should be avoided during pregnancy and breastfeeding unless specifically recommended by a qualified healthcare provider.
Adverse Effects
References
Monograph Sources
- [1] German Federal Institute for Drugs and Medical Devices (BfArM), Commission E. Monograph: Cynarae folium (Artichoke leaf). Bundesanzeiger (Federal Gazette), Germany (1990)
- [2] European Scientific Cooperative on Phytotherapy (ESCOP). Monograph: Cynarae folium (Artichoke leaf). ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products. 2nd ed. Stuttgart: Thieme (2003)
- [3] European Medicines Agency (EMA), Committee on Herbal Medicinal Products (HMPC). Community herbal monograph on Cynara scolymus L., folium. EMA/HMPC/150218/2009 (2011)
- [4] Hoffmann D. Medical Herbalism: The Science and Practice of Herbal Medicine. Rochester, VT: Healing Arts Press (2003)
- [5] Bone K, Mills S. Principles and Practice of Phytotherapy: Modern Herbal Medicine. 2nd ed.. Edinburgh: Churchill Livingstone/Elsevier (2013)
- [6] Kraft K. Artichoke leaf extract -- Recent findings reflecting effects on lipid metabolism, liver and gastrointestinal tracts. Phytomedicine (1997) ; 4 : 369-378 . DOI: 10.1016/S0944-7113(97)80049-9 . PMID: 23195590
Clinical Studies
- [7] Englisch W, Beckers C, Unkauf M, Ruepp M, Zinserling V. Efficacy of Artichoke dry extract in patients with hyperlipoproteinemia. Arzneimittelforschung (2000) ; 50 : 260-265 . DOI: 10.1055/s-0031-1300196 . PMID: 10758778
- [8] Bundy R, Walker AF, Middleton RW, Wallis C, Simpson HC. Artichoke leaf extract (Cynara scolymus) reduces plasma cholesterol in otherwise healthy hypercholesterolemic adults: A randomized, double blind placebo controlled trial. Phytomedicine (2008) ; 15 : 668-675 . DOI: 10.1016/j.phymed.2008.03.001 . PMID: 18424099
- [9] Walker AF, Middleton RW, Petrowicz O. Artichoke leaf extract reduces symptoms of irritable bowel syndrome in a post-marketing surveillance study. Phytother Res (2001) ; 15 : 58-61 . DOI: 10.1002/1099-1573(200102)15:1<58::AID-PTR805>3.0.CO;2-R . PMID: 11180525
- [10] Bundy R, Walker AF, Middleton RW, Booth J. Artichoke leaf extract reduces symptoms of irritable bowel syndrome and improves quality of life in otherwise healthy volunteers suffering from concomitant dyspepsia: a subset analysis. J Altern Complement Med (2004) ; 10 : 667-669 . DOI: 10.1089/acm.2004.10.667 . PMID: 15353023
- [11] Kirchhoff R, Beckers C, Kirchhoff GM, Trinczek-Gartner H, Petrowicz O, Reimann HJ. Increase in choleresis by means of artichoke extract. Phytomedicine (1994) ; 1 : 107-115 . DOI: 10.1016/S0944-7113(11)80027-9 . PMID: 23195882
- [12] Rangboo V, Noroozi M, Zavoshy R, Rezadoost SA, Mohammadpoorasl A. The effect of artichoke leaf extract on alanine aminotransferase and aspartate aminotransferase in the patients with nonalcoholic steatohepatitis. Int J Hepatol (2016) ; 2016 : 4030476 . DOI: 10.1155/2016/4030476 . PMID: 27293902
- [13] Sahebkar A, Pirro M, Banach M, Mikhailidis DP, Atkin SL, Cicero AF. Lipid-lowering activity of artichoke extracts: A systematic review and meta-analysis. Crit Rev Food Sci Nutr (2018) ; 58 : 2549-2556 . DOI: 10.1080/10408398.2017.1332572 . PMID: 28609140
Traditional Texts
- [14] Gebhardt R. Antioxidative and protective properties of extracts from leaves of the artichoke (Cynara scolymus L.) against hydroperoxide-induced oxidative stress in cultured rat hepatocytes. Toxicol Appl Pharmacol (1997) ; 144 : 279-286 . DOI: 10.1006/taap.1997.8130 . PMID: 9194411
- [15] Gebhardt R. Inhibition of cholesterol biosynthesis in HepG2 cells by artichoke extracts is reinforced by glucosidase pretreatment. Phytother Res (2002) ; 16 : 368-372 . DOI: 10.1002/ptr.960 . PMID: 12112295
Pharmacopeias & Reviews
- [16] European Directorate for the Quality of Medicines & HealthCare (EDQM). European Pharmacopoeia, 10th Edition: Artichoke leaf (Cynarae folium). Council of Europe, Strasbourg (2021)
- [17] World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 4: Folium Cynarae scolymi. World Health Organization, Geneva (2009)
Last updated: 2026-03-02 | Status: review
Unlock the Full Materia Medica
This monograph is part of our complete evidence-based herbal reference. Enter your email to get free, unlimited access to all of our monographs.
No spam, ever. Unsubscribe anytime.
You're In!
You now have full access to all of our herbal monographs.